Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 1—January 2021
Research

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines

Shalom Ben-Shimol, Noga Givon-Lavi, Leore Kotler, Bart Adriaan van der Beek, David Greenberg, and Ron DaganComments to Author 
Author affiliations: Ben-Gurion University of the Negev, Beer Sheva, Israel (S. Ben-Shimol, N. Givon-Lavi, L. Kotler, B.A. van der Beek, D. Greenberg, R. Dagan); Soroka University Medical Center, Beer Sheva (S. Ben-Shimol, N. Givon-Lavi, L. Kotler, D. Greenberg)

Main Article

Table 3

Antimicrobial nonsusceptibility among pneumococcal isolates in children age <24 mo, Israel, 2015–2017*

Drug and MIC Carriage in healthy children
Carriage in non-LRTI
Carriage in LRTI
Conjunctivitis
Otitis media
IPD
All outcomes
VT20-13, n = 261 NVT20, n = 706 p value VT20–13, n = 150 NVT20, n = 433 p value VT20–13, n = 141 NVT20, n = 253 p value VT2–13, n = 20 NVT20, n = 75 p value VT2–13, n = 26 NVT20, n = 40 p value VT20–13, n = 112 NVT20, n = 82 p value VT20–13, n = 710 NVT20, n = 1,589 p value
Penicillin >0.1 49 55 0.08 43 45 0.7 46 50 0.53 35 41 0.8 38 35 0.8 30 13 0.006 43 48 0.03
Penicillin >1.0 3 18 <0.001 5 17 <0.001 7 14 0.03 0 13 0.11 0 3 1.0 0 1 0.42 4 16 <0.001
Ceftriaxone >1.0 0 0 1.0 1 0 0.26 0 0 1.0 0 0 1.0 0 3 1.0 0 0 1.0 0 0 1.0
Erythromycin >21 31 15 <0.001 31 15 <0.001 28 19 0.03 30 16 0.2 19 5 0.1 8 9 1.0 26 15 <0.001
Tetracycline >23 31 18 <0.001 31 19 0.004 27 21 0.21 40 12 0.007 12 10 1.0 6 16 0.03 26 18 <0.001
Chloramphenicol >20 2 0 0.09 1 0 0.27 1 2 0.66 0 4 1.0 4 0 0.39 1 0 1.0 1 1 1.0
SXT >19 51 49 0.66 63 48 0.002 49 49 1.0 40 28 0.41 27 13 0.19 45 33 0.11 51 46 0.04
Clindamycin >19 19 7 <0.001 27 9 <0.001 24 7 <0.001 30 12 0.08 19 5 0.1 8 7 1.0 20 7 <0.001
MDR 32 19 <0.001 31 17 <0.001 27 21 0.22 35 13% 0.04 19 5 0.1 7 9 0.79 26 18 <0.001

*Values are percentage of total pneumococcal isolates except as indicated. IPD, invasive pneumococcal disease; LRTI, lower respiratory tract infection; MDR, multidrug resistance; NVT20, serotypes not included in PCV20; SXT, trimethoprim/sulfamethoxazole; VT20–13, additional 20-valent PCV (PCV20) serotypes, not included in 13-valent pneumococcal conjugate vaccine (PCV13).

Main Article

Page created: November 19, 2020
Page updated: December 21, 2020
Page reviewed: December 21, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external